CryoGen
This article was originally published in The Gray Sheet
Executive Summary
Raises $12 mil. in private placement led by Invesco Private Capital. San Diego-based CryoGen will use the funds to conclude clinical research and begin commercialization of its FirstOption Uterine Cryoblation therapy system to treat abnormal uterine bleeding. The miniature, closed-cycle cryoablation device, which is designed to allow physicians to ablate tissue at extremely low temperatures, is currently being evaluated at 11 centers in the U.S. The financing, which will also support R&D for cardiac applications of the cryoblation technology, brings the development-stage firm's total venture capital funding to $25.5 mil
You may also be interested in...
CryoGen On Track For Second Quarter Endometrial Ablation PMA Submission
Cryogen plans to file data in support of a premarket approval application during the second quarter to expand labeling for the First Option intrauterine cryosurgical probe to include specific references to endometrial ablation as a treatment for dysfunctional uterine bleeding.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.